Cresset Asset Management LLC Reduces Position in Boston Scientific Corporation $BSX

Cresset Asset Management LLC decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 10.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,891 shares of the medical equipment provider’s stock after selling 1,559 shares during the period. Cresset Asset Management LLC’s holdings in Boston Scientific were worth $1,401,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the first quarter worth $27,000. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $25,000. Colonial Trust Co SC grew its position in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 260 shares during the period. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Finally, Ameriflex Group Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on BSX shares. Robert W. Baird lifted their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Erste Group Bank raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, May 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $117.50.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 345,029 shares of company stock valued at $35,976,603 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $105.9080 on Thursday. The stock has a 50-day moving average price of $103.84 and a two-hundred day moving average price of $102.13. Boston Scientific Corporation has a 12-month low of $78.29 and a 12-month high of $108.94. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $156.93 billion, a PE ratio of 63.04, a price-to-earnings-growth ratio of 2.50 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.